Quest Diagnostics (DGX) — insider trading
Health Care · NYSE
Quest Diagnostics (DGX) has 41 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 41 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | WENTWORTH TIMOTHY C | Director | Grant / award / vesting (derivative) | 135 | — | $0 | Form 4 |
| 2026-09-01 | Davis J. E. | Director, Officer (CEO and President) | Open-market sale | 10,000 | $242.72 | $2.43M | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Option exercise / conversion (derivative) | 22,677 | $112.17 | $2.54M | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Bona fide gift | 1,000 | — | $0 | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Open-market sale | 430 | $244.51 | $105.1K | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Open-market sale | 6,237 | $243.63 | $1.52M | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Open-market sale | 16,010 | $242.88 | $3.89M | Form 4 |
| 2026-08-28 | PREVOZNIK MICHAEL E | Officer (SVP & General Counsel) | Option exercise / conversion | 22,677 | $112.17 | $2.54M | Form 4 |
| 2026-07-28 | DELANEY MARK E | Officer (SVP & Chief Commercial Officer) | Open-market sale | 1,600 | $235.18 | $376.3K | Form 4 |
| 2026-07-22 | DELANEY MARK E | Officer (SVP & Chief Commercial Officer) | Small acquisition | 34 | $206.81 | $7.0K | Form 4 |
| 2026-07-22 | Lassiter Wright III | Director | Small acquisition | 6 | $206.81 | $1.2K | Form 4 |
| 2026-07-22 | SAMAD SAM | Officer (Executive Vice President & CFO) | Grant / award / vesting | 102 | $206.81 | $21.1K | Form 4 |
| 2026-07-22 | MAIN TIMOTHY L | Director | Small acquisition | 21 | $206.81 | $4.3K | Form 4 |
| 2026-07-22 | Plewman Patrick | Officer (SVP for Diagnostic Services) | Small acquisition | 46 | $206.81 | $9.5K | Form 4 |
| 2026-07-22 | Gregg Vicky B | Director | Grant / award / vesting | 72 | $206.81 | $14.9K | Form 4 |
| 2026-07-22 | CARTER ROBERT B | Director | Small acquisition | 11 | $206.80 | $2.3K | Form 4 |
| 2026-07-22 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Small acquisition | 37 | $206.81 | $7.7K | Form 4 |
| 2026-07-01 | WENTWORTH TIMOTHY C | Director | Grant / award / vesting (derivative) | 144 | — | $0 | Form 4 |
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Option exercise / conversion (derivative) | 4,827 | $121.81 | $588.0K | Form 4 |
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Option exercise / conversion (derivative) | 3,320 | $127.73 | $424.0K | Form 4 |
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Open-market sale | 8,147 | $200.00 | $1.63M | Form 4 |
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Option exercise / conversion | 4,827 | $121.81 | $588.0K | Form 4 |
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Option exercise / conversion | 3,320 | $127.73 | $424.0K | Form 4 |
| 2026-06-01 | Davis J. E. | Director, Officer (CEO and President) | Open-market sale | 10,000 | $194.14 | $1.94M | Form 4 |
| 2026-05-20 | PFEIFFER GARY M | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | MORRISON DENISE M | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | Lassiter Wright III | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | RING TIMOTHY M | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | Doi Tracey | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | WENTWORTH TIMOTHY C | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | MAIN TIMOTHY L | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | Diaz Luis | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | Gregg Vicky B | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-05-20 | CARTER ROBERT B | Director | Grant / award / vesting | 1,142 | — | $0 | Form 4 |
| 2026-04-20 | DELANEY MARK E | Officer (SVP & Chief Commercial Officer) | Small acquisition | 37 | $194.70 | $7.2K | Form 4 |
| 2026-04-20 | KUPPUSAMY KARTHIK | Officer (SVP, Clinical Solutions) | Small acquisition | 39 | $194.70 | $7.6K | Form 4 |
| 2026-04-20 | Lassiter Wright III | Director | Small acquisition | 6 | $194.70 | $1.2K | Form 4 |
| 2026-04-20 | CARTER ROBERT B | Director | Small acquisition | 7 | $194.70 | $1.4K | Form 4 |
| 2026-04-20 | Gregg Vicky B | Director | Grant / award / vesting | 68 | $194.70 | $13.2K | Form 4 |
| 2026-04-20 | Plewman Patrick | Officer (SVP for Diagnostic Services) | Small acquisition | 49 | $194.70 | $9.5K | Form 4 |
| 2026-04-20 | SAMAD SAM | Officer (Executive Vice President & CFO) | Grant / award / vesting | 108 | $194.70 | $21.0K | Form 4 |
Ask the chat about DGX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Quest Diagnostics (DGX).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.